Analyst Initiates ImmunityBio Coverage
This is a news story, published by Yahoo Finance, that relates primarily to Bacillus Calmette-Guérin news.
Bacillus Calmette-Guérin news
For more Bacillus Calmette-Guérin news, you can click here:
more Bacillus Calmette-Guérin newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Bladder Cancer Focused ImmunityBio. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest cancer immunotherapy news, Bladder Cancer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
immune checkpoint therapiesBenzinga
•Analyst initiates coverage on ImmunityBio Inc. ( NASDAQ:IBRX) with a $30 price target
64% Informative
EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX) The analyst initiates with a Buy rating and a price target of $ 30 .
The FDA approved ImmunityBio ’s Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin ( BCG ) for BCG -unresponsive non-muscle invasive bladder cancer.
VR Score
54
Informative language
53
Neutral language
1
Article tone
formal
Language
English
Language complexity
68
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
7
Source diversity
1
Affiliate links
no affiliate links